

company announcement

Novo Nordisk – major shareholder announcement

Bagsværd, Denmark, 14 February 2022 – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 8 February 2022 holds B shares equal to 5.05% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act.

The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to 5.07% of the entire share capital and below 5% of the voting rights.

For a full chain of controlled undertakings through which the voting rights and/or the financial instruments are held, please see the annex.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Novo Allé 2880 Bagsværd Denmark Telephone: +45 4444 8888 Internet: www.novonordisk.com CVR no: 24 25 67 90 Company announcement No 12 / 2022

Further information

Media: Martin Havtorn Petersen Michael Bachner (US)	+45 3075 5246 +1 609 664 7308	<u>mhpz@novonordisk.com</u> <u>mzyb@novonordisk.com</u>
Investors:		
Daniel Muusmann Bohsen	+45 3075 2175	<u>dabo@novonordisk.com</u>
Ann Søndermølle Rendbæk	+45 3075 2253	arnd@novonordisk.com
David Heiberg Landsted	+45 3077 6915	<u>dhel@novonordisk.com</u>
Jacob Martin Wiborg Rode Mark Joseph Root (US)	+45 3075 5956 +1 848 213 3219	jrde@novonordisk.com mjhr@novonordisk.com

Novo Nordisk A/S Investor Relations Novo Allé 2880 Bagsværd Denmark

Telephone: +45 4444 8888 Internet: www.novonordisk.com CVR no: 24 25 67 90 Company announcement No 12 / 2022

Annex

Name	% of voting rights if	% of voting rights	Total of both
	it equals or is higher	through financial	if it equals or
	than the notifiable	instruments if it equals	is higher
	threshold	or is higher than the	than the
		notifiable threshold	notifiable
			threshold
BlackRock Japan Co., Ltd.			Below 5%
BlackRock Investment			Below 5%
Management, LLC			
BlackRock Investment			Below 5%
Management (UK) Limited			
BlackRock Investment			Below 5%
Management (Australia)			
Limited			
Blackrock International			Below 5%
Limited			
BlackRock Fund Advisors			Below 5%
BlackRock Financial			Below 5%
Management, Inc.			
BlackRock Asset			Below 5%
Management North Asia			
Limited			
BlackRock Asset			Below 5%
Management Deutschland			
AG			
BlackRock Asset			Below 5%
Management Canada			
Limited			
BlackRock Advisors, LLC			Below 5%
BlackRock (Singapore)	İ.		Below 5%
Limited			
BlackRock Asset			Below 5%
Management Ireland			
Limited			
Aperio Group, LLC			Below 5%
			20.011 270
	1	1	1